BioDelivery Sciences International (BDSI) Posts Earnings Results

BioDelivery Sciences International (NASDAQ:BDSI) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04, Morningstar.com reports. BioDelivery Sciences International had a negative net margin of 103.01% and a negative return on equity of 278.79%. The business had revenue of $14.16 million during the quarter, compared to analysts’ expectations of $14.21 million.

Shares of BDSI stock traded up $0.09 during trading hours on Friday, reaching $3.78. 688,322 shares of the stock were exchanged, compared to its average volume of 731,159. BioDelivery Sciences International has a 12-month low of $1.70 and a 12-month high of $4.14. The company has a current ratio of 3.16, a quick ratio of 2.90 and a debt-to-equity ratio of 1.21. The stock has a market cap of $224.54 million, a PE ratio of -9.69 and a beta of 0.09.

In related news, Director Francis E. Odonnell, Jr. sold 151,039 shares of BioDelivery Sciences International stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $2.84, for a total transaction of $428,950.76. Following the completion of the transaction, the director now directly owns 520,482 shares of the company’s stock, valued at approximately $1,478,168.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $3.84, for a total transaction of $30,720.00. Following the transaction, the director now directly owns 522,187 shares of the company’s stock, valued at $2,005,198.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 175,039 shares of company stock valued at $503,991. 13.26% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Fosun International Ltd purchased a new position in shares of BioDelivery Sciences International during the 3rd quarter worth about $1,462,000. JPMorgan Chase & Co. boosted its stake in shares of BioDelivery Sciences International by 35.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 267,874 shares of the specialty pharmaceutical company’s stock worth $750,000 after purchasing an additional 70,633 shares during the period. Wells Fargo & Company MN boosted its stake in shares of BioDelivery Sciences International by 121.7% during the 3rd quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock worth $331,000 after purchasing an additional 64,803 shares during the period. Alpha Omega Wealth Management LLC purchased a new position in shares of BioDelivery Sciences International during the 3rd quarter worth about $3,668,000. Finally, Essex Investment Management Co. LLC purchased a new position in shares of BioDelivery Sciences International during the 3rd quarter worth about $1,057,000. 46.10% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have commented on BDSI shares. HC Wainwright set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, October 8th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 24th. Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 7th. Finally, Janney Montgomery Scott lifted their price objective on shares of BioDelivery Sciences International to $5.00 and gave the stock a “buy” rating in a research note on Friday, November 2nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $4.54.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/11/10/biodelivery-sciences-international-bdsi-posts-earnings-results.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: Why is Cost of Capital Important?

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply